Gabather AB (SE:GABA)

:GABA

GABA

Gabather AB

RESEARCH TOOLSreports

Want to see SE:GABA full AI Analyst Report?

Gabather AB (GABA) Price & Analysis

0 Followers

GABA Stock Chart & Stats

kr0.04

>-kr0.01(-12.89%)

At close: Mar 06 4:00 PM EST

kr0.04

>-kr0.01(-12.89%)

Day’s Range― - ―

52-Week Rangekr0.02 - kr0.13

Previous CloseN/A

Volume42.79K

Average Volume (3M)488.51K

Market Cap

kr20.55M

Enterprise Valuekr5.69M

Total Cash (Recent Filing)kr6.04M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.00

Next Earnings

Aug 27, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding491,634,160

10 Day Avg. Volume541,248

30 Day Avg. Volume488,507

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-6.10

Price to Sales (P/S)0.00

P/FCF Ratio-0.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial Leverage (zero Debt)Zero reported debt meaningfully lowers near-term default and interest-service risk and gives management flexibility in structuring future financings or partnerships. For a pre-commercial biotech this durable balance-sheet trait reduces refinancing pressure over the next several quarters.

Improving Net Loss TrendA multi-year reduction in reported losses signals improving cost control or more efficient R&D spend allocation. Sustained narrowing of losses over successive years enhances runway prospects and makes future financing needs smaller or less dilutive if trends continue.

Partnering/out-licensing Focused Business ModelA clear monetization path via licensing and milestone/royalty streams aligns with a small R&D-focused biotech operating model. This structural strategy leverages external commercialization capabilities, limiting required scale-up investments and allowing value capture without building full commercial infrastructure.

Bears Say

Pre-revenue OperationsBeing pre-revenue means intrinsic value is contingent on successful clinical and licensing outcomes rather than predictable sales. This structural reliance on future milestones increases funding uncertainty and makes near-term cash needs and financing decisions fundamental to viability.

Negative Equity / Eroded Capital BaseNegative equity indicates accumulated losses have exhausted net capital, reducing the balance sheet's capacity to absorb shocks and potentially complicating lender or partner perceptions. Structurally, this elevates the likelihood of dilutive financings or urgent recapitalization needs.

Consistent Negative And Volatile Cash FlowPersistent negative and variable operating cash flow creates ongoing dependence on external financing. Volatility in burn rates increases the risk of timing mismatches with funding markets and can force accelerated or dilutive capital raises, directly affecting program continuity and long-term strategy execution.

GABA FAQ

What was Gabather AB’s price range in the past 12 months?

Gabather AB lowest stock price was kr0.02 and its highest was kr0.13 in the past 12 months.

What is Gabather AB’s market cap?

Gabather AB’s market cap is kr20.55M.

When is Gabather AB’s upcoming earnings report date?

Gabather AB’s upcoming earnings report date is Aug 27, 2026 which is in 72 days.

How were Gabather AB’s earnings last quarter?

Gabather AB released its earnings results on May 28, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.

Is Gabather AB overvalued?

According to Wall Street analysts Gabather AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gabather AB pay dividends?

Gabather AB does not currently pay dividends.

What is Gabather AB’s EPS estimate?

Gabather AB’s EPS estimate is 0.

How many shares outstanding does Gabather AB have?

Gabather AB has 491,634,160 shares outstanding.

What happened to Gabather AB’s price movement after its last earnings report?

Gabather AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Gabather AB?

Currently, no hedge funds are holding shares in SE:GABA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gabather AB

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.